not used title
not used title
More than 1,150 medicines were excluded from at least one of the three largest PBMs’ standard commercial formularies in 2022, according to a new report from Xcenda. The report is further evidence of how PBMs are making it harder for patients to get the prescription medicines they need.
The three largest PBMs — CVS Caremark, Express Scripts and OptumRx — manage 80% of all prescriptions and own, or are owned by, some of the largest insurers in the country. These large corporations influence which medicines are covered by insurance and how much patients pay out of pocket. And as this new report shows, patients are facing fewer options:
- Of the 1,156 medicines excluded in 2022, almost half were brand medicines without a generic or biosimilar alternative.
- The three PBMs frequently excluded lower list priced insulins from their formularies, instead choosing to cover higher list price versions with larger rebates.
- Compared to 2014, almost six times more cardiovascular treatments were excluded from one or more PBM formulary in 2022.
Xcenda finds that these formulary exclusions can undermine patient and provider choice and may prevent a patient from accessing a particular medicine unless they pay completely out of pocket or undertake a burdensome appeals or exceptions process.
The report also found:
- Medicines to treat multiple sclerosis, mental health disorders, Parkinson’s disease, epilepsy, and other serious complex central nervous system conditions, experienced particularly dramatic growth in exclusions from 2017 to 2022, with the number of medicines excluded by one or more PBM increasing by an average of 51% each year.
- PBM exclusions of medicines that were approved through one of the four Food and Drug Administration (FDA) expedited review pathways have accelerated rapidly in recent years. In total, 178 unique medicines were excluded from one or more PBM formulary for at least one year between 2014 and 2022.
Health care decisions should be between the patient and the physician, not middlemen. As PhRMA President and CEO Steve Ubl noted:
“PBMs have earned their reputation as middlemen by finding ways to stand between patients and their medicines. These tactics may lead to lower costs for health plans, but they can also lead to higher out-of-pocket costs for patients and restrict access to prescription medicines. We need to make insurance work like it's supposed to and bring more accountability to middlemen who are getting in the way of patients and the lifesaving care they need.”
To read the full report, click here.
Brian Newell
is Deputy Vice President of Public Affairs at PhRMA and serves as lead spokesperson for national media. Before joining PhRMA in 2020, he served as managing director of strategic communications for the Biotechnology Innovation Organization (BIO). Prior to BIO, Brian worked on Capitol Hill for ten years, including roles on the Education and Workforce Committee, the House Republican Conference and the Ways and Means Committee. Brian graduated with a BA in Political Science from the University of Maine, his home state. He enjoys spending time with his wife and two children – especially summer vacations on the lake in Maine.
Brian Newell
Insurers routinely block seniors’ access to medicines in Medicare Part D
March 18, 2026
New study: PBMs and commercial insurers are quietly blocking prescription access
July 30, 2025
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
March 13, 2025
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
October 30, 2024
Guest Post: My health care vote
October 29, 2024
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
October 28, 2024
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
September 24, 2024
Key voter insights two months from Election Day
September 10, 2024
Patient priorities in the 2024 election
September 10, 2024
Three things to know about the United Nations’ new HIV/AIDS report
July 31, 2024
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
July 30, 2024
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
July 22, 2024
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
July 9, 2024
ICYMI: What patients care about this election year
June 24, 2024
ICYMI: Misaligned policies undermine patient access
June 6, 2024
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
June 5, 2024
Ongoing federal probes shed light on PBM and insurer practices
May 20, 2024
Critics repeat same, misleading narrative on potential “costs” of new medicines
May 7, 2024
WTAS: The consequences of consolidation and vertical integration
May 6, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
April 16, 2024
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
April 9, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
ICYMI: When middlemen get in the way, it’s the patients who lose
December 5, 2023
Increased use of prior authorization in Medicaid is blocking access for patients
November 28, 2023
New analysis of patient access restrictions in the United Kingdom
November 21, 2023
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
November 15, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
One year to Election Day: Four voter priorities to watch
November 6, 2023
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
September 5, 2023
AARP’s latest misleading report
August 11, 2023
New report: Hospitals mark up medicine prices 500%
August 2, 2023
read more
August 2, 2023
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
July 26, 2023
Three things to know from the latest Patient Experience Survey
July 20, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
ICYMI: PBM exec admits choosing profits over patients
June 2, 2023
Insulin: Key Facts on Access & Affordability
May 10, 2023
4 key facts on medicine prices and spending
May 9, 2023
4 Things to know about PhRMA’s new 50-state poll
May 4, 2023
Three facts about health care spending
April 25, 2023
AHIP’s latest misinformation campaign & what it’s trying to hide
April 24, 2023
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
April 7, 2023
States can support access to medicine as COVID-19 Public Health Emergency ends
April 5, 2023
Arkansas puts patients first with new share the savings law
April 4, 2023
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
March 29, 2023
Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions
March 2, 2023
Holding pharmacy benefit managers accountable
February 23, 2023
Stopping pharmacy benefit managers from “gaming the system”
February 22, 2023
Senate hearing to examine bipartisan reforms to rein in middlemen
February 16, 2023
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
January 31, 2023
ICYMI: Cancer death rate continues to decline due to treatment advances
January 25, 2023
Novel medicines approved in 2022 offer increased treatment options for patients
January 23, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
Study finds hepatitis C cure saved Medicaid $15 billion
January 5, 2023
In their own words: Insured Americans support policy reforms that address access and affordability concerns
December 14, 2022
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
December 9, 2022
In their own words: Financial barriers exacerbate access challenges for insured Americans
December 8, 2022
Medicare Part D open enrollment and what recent changes mean for beneficiaries
November 17, 2022
New data show how insurers and middlemen shift Rx costs onto patients
November 16, 2022
In their own words: Insured Americans struggle to navigate complex coverage
October 26, 2022
Many seniors are paying more for Part D medicines than their insurer
October 18, 2022
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
October 7, 2022
Busting 3 Myths About Copay Coupons
October 5, 2022
Mental Illness Awareness Week – A time for reflection
October 3, 2022
Navigating the patient experience: Burdens and barriers standing between patients and their care
September 12, 2022
Making coupons count for patients at the pharmacy counter
August 25, 2022
Insulin and reconciliation
August 15, 2022
Making coupons count for patients with HIV
August 8, 2022
By the Numbers: Patients lose when the government sets prices
July 8, 2022
Patients win as West Virginia implements first-in-nation share the savings policy
July 8, 2022
3 things voters are concerned about when it comes to their health care coverage
July 7, 2022
Prescription drug prices are not fueling inflation
July 6, 2022
Copay assistance is a lifeline for patients. So why are insurers blocking it?
June 29, 2022
CMS coverage decision restricts access to treatments for Alzheimer’s disease
June 22, 2022
New poll shows voters sounding the alarm on health insurance companies and PBMs
June 6, 2022
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
May 31, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
May 9, 2022
Annual projections from NHE compared to actual health care spending
May 5, 2022
Study finds insurance barriers disproportionately burden patients with chronic illness
May 4, 2022
What’s really happening when it comes to prescription drug costs
April 27, 2022
5 public opinion polling trends to watch
April 22, 2022
Analysis: States can help patients save nearly $1,000 annually on their medicines
April 21, 2022
New analysis confirms hospitals markup prices for oncology therapies
April 21, 2022
How standardized plans can improve patients’ access to medicines
April 18, 2022
The patient experience: Uncovering the barriers to care for insured Americans
March 28, 2022
Correcting the record: Putting medicine costs and spending in context
March 24, 2022
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
March 16, 2022
Guest Post: If we truly want to cure complex diseases, politicians should reject price setting
March 14, 2022
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
March 11, 2022
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
March 8, 2022
The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved
February 28, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
PhRMA submits comments urging CMS to withdraw coverage proposal
February 11, 2022
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
February 8, 2022
Research and development continues long after a medicine is initially approved
February 1, 2022
New comments outline ways to counteract cost-shifting insurance trends
January 28, 2022
Patients need to pay less for their medicines. States can help.
January 26, 2022
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
January 25, 2022
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
January 21, 2022
New study finds more than half of brand medicine spending goes to the supply chain and others
January 7, 2022
New NHE data show the true picture of health care spending
December 22, 2021
3 things to know about the importance of post-approval research and development
December 6, 2021
Guest post: Congress should not put future innovation at risk
November 29, 2021
What is missing in the current drug pricing plan
November 23, 2021
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
November 19, 2021
In the current health care debate, Congress has lost sight of what matters to U.S. voters
November 15, 2021
The patient experience: Insurance design hurdles lead to access issues for too many Americans
October 28, 2021
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
October 19, 2021
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
October 18, 2021
New poll shows Americans reject Medicare negotiation once they learn more about the policy
October 15, 2021
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
October 14, 2021
What is Kaiser Family Foundation up to?
October 12, 2021
Recognizing Hepatitis R&D on World Hepatitis Day
July 28, 2021
New reports shed light on key facts about medicines and affordability
June 8, 2021
How strengthening the biosimilar marketplace benefits patients
May 18, 2021
New report demonstrates development of new medicines relies on private sector expertise and investment
May 10, 2021
West Virginia becomes the first state to lower patient costs by sharing the savings
April 20, 2021
Getting the 340B program back on track in 2021
March 10, 2021
Top five issues voters want addressed in the administration’s first 100 days
February 18, 2021
Insurers shift medicine costs to patients with severe chronic illnesses
February 1, 2021
Election insights: Voter priorities in the states
December 17, 2020
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
November 19, 2020
Survey found insurance premiums grew faster than inflation in 2020
October 20, 2020
Growth in innovative, value-based contracts holds promise for the health system and for patients
September 24, 2020
Innovative contracts drive access for patients and value for the system
September 9, 2020
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
August 19, 2020
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
August 12, 2020
Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs
August 6, 2020
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report
August 5, 2020
New data show commercially insured patients face increasingly high cost sharing for brand medicines
July 30, 2020
Payers subject 80% of new RA and MS patients to utilization management restrictions
July 22, 2020
ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access
June 1, 2020
New rule makes it harder for patients to lower their out-of-pocket costs
May 20, 2020
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
April 20, 2020
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
March 3, 2020
Addressing barriers that inhibit value-based contracts
February 21, 2020
Fact Check: HCCI analysis overstates medicine spending and prices
February 19, 2020
Cancer medicines cost twice as much at hospitals, study finds
January 21, 2020
Nearly 50% of brand medicine spending goes to the supply chain and others
January 9, 2020
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
November 4, 2019
More evidence that medicine prices are growing at slowest rate in decades
October 4, 2019
Survey shows out-of-pocket costs top health care concern for voters
October 2, 2019
Four reasons why the radical Pelosi Plan is the wrong approach
September 24, 2019
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
September 10, 2019
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
September 4, 2019
Three things to know about the Part D GAO report
August 16, 2019
Setting the record straight on international reference pricing
July 16, 2019
New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?
July 9, 2019
Study finds hospitals continue to mark up medicines up to 500% of their cost
July 9, 2019
Three reasons why the latest Rx Savings Solutions analysis is misleading
July 2, 2019
"If Washington isn’t careful, we might leave innovation behind"
June 24, 2019
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
May 15, 2019
New study finds hospitals continue to push patients to costlier outpatient settings
May 13, 2019
4 Things to know about the IQVIA “Medicine Use and Spending” report
May 9, 2019
Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”
May 9, 2019
Fact Check: How the Part B International Pricing Index model threatens patient access
March 29, 2019
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
March 20, 2019
The PBM story you haven’t heard: Hidden fees quadrupled in two years
March 20, 2019
Health Affairs study misses the mark on medicine costs
January 28, 2019
PhRMA comments to administration on Medicare Part D proposed rule
January 25, 2019
New government data show medicine price growth continues to decline
January 18, 2019
ICYMI: New study reinforces dangers of proposed IPI model
January 15, 2019
Groups sound the alarm on administration’s new Part B proposal
November 14, 2018
4 things you need to know about the administration’s latest Part B proposal
November 5, 2018
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
November 2, 2018
Americans want to know more than just the list price of a medicine—and we’re answering their call
October 15, 2018
What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
October 15, 2018
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
October 4, 2018
Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program
September 24, 2018
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
September 19, 2018
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
September 13, 2018
New study finds some hospitals mark up medicine prices at least 700 percent
September 5, 2018
69 percent of patients abandon medicines when cost sharing is more than $250
August 23, 2018
New analysis in Health Affairs reinforces one-third of medicine list price rebated back to supply chain
August 13, 2018
How much do you know about Medicare Part B?
July 31, 2018
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
July 24, 2018
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
July 16, 2018
Event next week: Supporting the next generation of lifesaving medicines
July 12, 2018
New data show patients’ out-of-pocket costs are rising faster than their insurers’ costs
July 9, 2018
Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge
June 28, 2018
Medicare Part D cliff ahead
June 21, 2018
Part D cliff looms for seniors, as program stability could be in jeopardy
June 18, 2018
New analysis shows that more medicines worldwide are available to U.S. patients
June 5, 2018
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
June 1, 2018
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
May 31, 2018
Event tomorrow: Improving patient access to lifesaving medicines
May 22, 2018
Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than $350 annually
May 17, 2018
New “Let’s Talk About Medicare” campaign focuses on solutions to improve affordability and predictability for seniors in Part D
May 9, 2018
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
May 4, 2018
Event tomorrow: Making the biopharmaceutical supply chain work for patients
May 2, 2018
Spending on medicines grew less than one percent in 2017
April 19, 2018
Patients pay the price when hospitals mark up cancer medicines
April 5, 2018